Datapoint: BMS, Nektar End $2B Partnership

Bristol Myers Squibb and Nektar Therapeutics are scrapping their $2 billion partnership. The companies were testing combinations of Opdivo and bempegaldesleukin, an experimental Nektar drug designed to stimulate interleukins. The combo showed poor results in melanoma, renal cell carcinoma and urothelial cancer. For the treatment of urothelial cancer, Opdivo currently holds covered or better status for 67% of all insured lives under the pharmacy benefit. Under the medical benefit, 88% of lives have covered or better access to Opdivo.

SOURCE: MMIT Analytics, as of 4/19/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 3

Datapoint: AstraZeneca, Merck Pull Lynparza in Ovarian Cancer

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 29

Datapoint: Nebraska Awards Medicaid Contracts

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 28

Datapoint: Lilly Scores Sweeping Label Expansion for Retevmo

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today